<p>There are many human cancers which actively synthesize specific characteristic proteins such as melanomas, thyroid cancer and squamous cell carcinoma. Many cancer researchers have of course tried to utilize this specific activity as a key for the selective treatment of cancers. In the past for ex
Neutron Beam Design, Development, and Performance for Neutron Capture Therapy
β Scribed by R. M. Brugger, G. Constantine, O. K. Harling, F. J. Wheeler (auth.), Otto K. Harling, John A. Bernard, Robert G. Zamenhof (eds.)
- Publisher
- Springer US
- Year
- 1990
- Tongue
- English
- Leaves
- 339
- Series
- Basic Life Sciences 54
- Edition
- 1
- Category
- Library
No coin nor oath required. For personal study only.
β¦ Synopsis
For this Workshop, the organizers have attempted to invite experts from all known centers which are engaged in neutron beam development for neutron capture therapy. The Workshop was designed around a series of nineteen invited papers which dealt with neutron source design and development and beam characterization and performance. Emphasis was placed on epithermal beams because they offer clinical advantages and are more challenging to implement than thermal beams. Fission reactor sources were the basis for the majority of the papers; however three papers dealt with accelerator neutron sources. An additional three invited papers provided a summary of clinical results of Ncr therapy in Japan between 1968 and 1989 and overviews of clinical considerations for neutron capture therapy and of the status of tumor targeting chemical agents for Ncr. Five contributed poster papers dealing with NCT beam design and performance were also presented. A rapporteurs' paper was prepared after the Workshop to attempt to summarize the major aspects, issues, and conclusions which resulted from this Workshop. Many people contributed to both the smooth functioning of the Workshop and to the preparation of these proceedings. Special thanks are reserved for Ms. Dorothy K.
β¦ Table of Contents
Front Matter....Pages i-xi
Front Matter....Pages 1-1
Rapporteursβ Report....Pages 3-12
Front Matter....Pages 13-13
Clinical Results of Boron Neutron Capture Therapy....Pages 15-21
Clinical Considerations for Neutron Capture Therapy of Brain Tumors....Pages 23-35
Tumor Targeting Agents for Neutron Capture Therapy....Pages 37-47
Front Matter....Pages 49-49
Monte Carlo Methods of Neutron Beam Design for Neutron Capture Therapy at the Mit Research Reactor (MITR-II)....Pages 51-69
Neutron Capture Therapy Beam Design at Harwell....Pages 71-82
Physics Design for the Brookhaven Medical Research Reactor Epithermal Neutron Source....Pages 83-95
A Calculational Study of Tangential and Radial Beams in HIFAR for Neutron Capture Therapy....Pages 97-107
Research on Neutron Beam Design for BNCT at the Musashi Reactor....Pages 109-124
Neutron Beam Studies for a Medical Therapy Reactor....Pages 125-139
Investigation of Neutron Beams for the Realization of Boron Neutron Capture Therapy....Pages 141-151
Intermediate Energy Neutron Beams from the MURR....Pages 153-166
Front Matter....Pages 167-167
Progress Towards Boron Neutron Capture Therapy at the High Flux Reactor Petten....Pages 169-183
Installation and Testing of an Optimized Epithermal Neutron Beam at the Brookhaven Medical Research Reactor (BMRR)....Pages 185-199
Neutron Capture Therapy Beams at the MIT Research Reactor....Pages 201-218
Georgia Tech Research Reactor Epithermal Beam....Pages 219-227
Neutron Beam Design and Performance for BNCT in Czechoslovakia....Pages 229-233
Neutron Spectrum Measurements in the Aluminum Oxide Filtered Beam Facility at the Brookhaven Medical Research Reactor....Pages 235-245
Front Matter....Pages 247-247
The Possible Use of a Spallation Neutron Source for Neutron Capture Therapy with Epithermal Neutrons....Pages 249-258
A Versatile, New Accelerator Design for Boron Neutron Capture Therapy: Accelerator Design and Neutron Energy Considerations....Pages 259-270
Front Matter....Pages 247-247
An Experimental Study of the Moderator Assembly for a Low-Energy Proton Accelerator Neutron Irradiation Facility for BNCT....Pages 271-280
Front Matter....Pages 281-281
Monte Carlo Based Dosimetry and Treatment Planning for Neutron Capture Therapy of Brain Tumors....Pages 283-305
Epithermal Beam Development at the BMRR: Dosimetric Evaluation....Pages 307-316
A Beam-Modification Assembly for Experimental Neutron Capture Therapy of Brain Tumors....Pages 317-320
Biomedical Irradiation System for Boron Neutron Capture Therapy at the Kyoto University Reactor....Pages 321-339
Back Matter....Pages 341-353
β¦ Subjects
Nuclear Medicine;Ultrasound;Animal Physiology;Biophysics and Biological Physics
π SIMILAR VOLUMES
<p><p>Neutron capture therapy (NCT) is based on the ability of the non-radioactive isotope boron-10 to capture thermal neutrons with very high probability and immediately to release heavy particles with a path length of one cell diameter, which in principle allows for tumor cell-selective high-LET p
<p>Despite the many advances made in the diagnosis and therapy of cancer, the mortality rate is still about half that of the incidence rate. However, the odds are not evenly distributed. Prognosis for some cancers is good, but for others, few patients will survive 12 months. This latter group of can
<p>Binary systems for the treatment of cancer potentially are among the most attractive of the new therapeutic modalities that currently are under investigation. The basicconcept is to selectivelydestroy malignantcells whileconcomitantlysparing normal tissue. Neutron capture therapy (NCT) is the bin
<p>Since Locher first suggested Boron Neutron Capture Therapy (BNCT) in 1936, this theoretically ideal system has intrigued investigators. Unfortunately, the first clinical trials between 1951-1961 were not successful. However, they served to implant firmly the seed of BNCT, the growth of which has
IAEA, Vienna, 2001, - 302 p. (ΠΠ½Π³. ΡΠ·ΡΠΊ)<div class="bb-sep"></div>There are about 6000 new glioblastoma multiform brain tumours diagnosed each year in the United States of America alone. This cancer is usually fatal within six months of diagnosis even with current standard treatments. Research on bo